Publications by authors named "G T Obrador"
Total Gestational Weight Gain Is Explained by Leptin and Body Fat, Regardless of Pre-Pregnancy Body Mass Index and Other Adipokines, in Mexican Adolescents.
Gabriela Chico-Barba Reyna Sámano Hugo Martínez-Rojano Rosa María Morales-Hernández Edgar Barrientos-Galeana Gregorio T Obrador
Nutrients
July 2024
Pre-pregnancy body mass index (pBMI) is a predictor of gestational weight gain (GWG). However, other factors, such as adipokines and inflammation markers, may also be associated with GWG. The aim of the study was to determine the association of leptin, adiponectin, irisin, and C-reactive protein, with GWG in adolescents.
View Article and Find Full Text PDFArticle Synopsis
- Integrated kidney care connects preventative measures for chronic kidney disease with health services for those already affected, focusing on smooth transitions between different stages of the disease and treatment options.
- Supportive care is crucial for individuals with kidney failure, yet it is often lacking or poorly integrated, particularly in low- and middle-income countries where resources are limited.
- The International Society of Nephrology has developed consensus definitions and guidelines to improve the understanding and implementation of conservative kidney management and supportive care in these under-resourced settings.
Article Synopsis
- - The ASCEND-NHQ trial investigated the effectiveness of daprodustat in increasing hemoglobin levels and improving fatigue in adults with chronic kidney disease (CKD) stages 3-5, comparing it to a placebo over 28 weeks.
- - Results showed that participants taking daprodustat experienced a significant mean change in hemoglobin (1.58 g/dl) compared to the placebo group (0.19 g/dl), with 77% of daprodustat users achieving a 1 g/dl increase.
- - Additionally, the SF-36 Vitality score (which measures fatigue) improved more for those on daprodustat (7.3 points) than those on placebo (1.
Article Synopsis
- Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) affects 10-15% of chronic dialysis patients, and a study compared the investigational drug daprodustat with standard ESA treatment to understand the characteristics and predictors of this issue.
- The study recruited 2,964 ESA-treated chronic dialysis patients and defined ESA hyporesponsiveness using specific criteria, finding that about 12% of participants were hyporesponsive.
- Key predictors included geographic region (especially Latin America), lower body mass index, younger age, and certain blood levels, along with additional factors like female sex and a history of heart failure; notably, the geographic finding suggests a need for further research.